JNJ-74856665

DRUG4 trials

Sponsors

Janssen-Cilag International NV, Yoshinari Nozomi, Janssen Research & Development, LLC

Conditions

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteLeukemia, Myeloid, Acute Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-HodgkinLymphoma, Non-HodgkinMyelodysplastic SyndromesNeoplasms

Phase 1

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CompletedNCT04609826

Janssen Research & Development, LLCAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes

Start: 2020-11-26End: 2025-08-25Updated: 2025-10-01

A rollover study for continued study treatment and ongoing safety monitoring

RecruitingISRCTN87946208

Janssen-Cilag International NVNon-Hodgkin lymphoma and chronic lymphocytic leukemia Cancer

Start: 2024-12-31Target: 77Updated: 2025-03-31

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Enrolling by invitationNCT06788509

Janssen Research & Development, LLCLeukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin +4

Start: 2024-12-30End: 2028-10-30Target: 120Updated: 2026-07-06

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Active, not recruitingJPRN-jRCT2041240191

Yoshinari NozomiLeukemia, Myeloid, Acute Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin

Start: 2025-02-19Target: 80Updated: 2026-06-29